Developments in the Classification and Treatment of the Juvenile Idiopathic Inflammatory Myopathies

Rheumatic Disease Clinics of North America

Volumn 39, Issue 4, 2013, Pages 877-904

  Rider, Lisa G ^a,b   Katz, James D ^b   Jones, Olcay Y ^b,c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Biologic therapies; Juvenile dermatomyositis; Juvenile myositis; Juvenile polymyositis; Myositis specific autoantibodies; Overlap myositis; Treatment

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AUTOANTIBODY; CORTICOSTEROID; CORTICOTROPIN; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYOSITIS ASSOCIATED AUTOANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; CALCINOSIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; ENDURANCE TRAINING; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; JUVENILE DERMATOMYOSITIS; JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHY; JUVENILE POLYMYOSITIS; MACROPHAGIC MYOFASCIITIS; MALIGNANT NEOPLASTIC DISEASE; MYOSITIS; OTITIS MEDIA; PATHOPHYSIOLOGY; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; RASH; RESISTANCE TRAINING; REVIEW; SEROLOGY; SINUSITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

BIOLOGIC THERAPIES; JUVENILE DERMATOMYOSITIS; JUVENILE MYOSITIS; JUVENILE POLYMYOSITIS; MYOSITIS-SPECIFIC AUTOANTIBODIES; OVERLAP MYOSITIS; TREATMENT;

ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; CHILD; CYCLOSPORINE; DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; METHYLPREDNISOLONE; MYOSITIS; PREDNISONE;

EID: 84886796795     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.06.001     Document Type: Review

References (138)

1. Bohan A., Peter J.B. Polymyositis and dermatomyositis. Parts 1 and 2. NEngl J Med 1975, 292:344-347. 3403-7.
2. Brown V.E., Pilkington C.A., Feldman B.M., et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) 2006, 45:990-993.
3. Rider L.G., Miller F.W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997, 23:619-655.
4. Rider L.G., Miller F.W. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011, 305:183-190.
5. Shah M., Targoff I.N., Rice M.M., et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 2013, 92:25-41.
6. Mohassel P., Mammen A.L. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: a review. Muscle Nerve 2013, [Epub ahead of print]. 10.1002/mus.23854.
7. McCann L.J., Juggins A.D., Maillard S.M., et al. The juvenile dermatomyositis national registry and repository (UK and Ireland)-clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006, 45:1255-1260.
8. Sato J.O., Sallum A.M., Ferriani V.P., et al. ABrazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009, 27:1031-1038.
9. Guseinova D., Consolaro A., Trail L., et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 2011, 29:117-124.
10. Sallum A.M., Pivato F.C., Doria-Filho U., et al. Risk factors associated with calcinosis of juvenile dermatomyositis. JPediatr (Rio J) 2008, 84:68-74.
11. Bingham A., Mamyrova G., Rother K.I., et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008, 87:70-86.
12. Wedderburn L.R., McHugh N.J., Chinoy H., et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007, 46:1786-1791.
13. Huber A.M., Mamyrova G., Lee J.A., et al. Illness features associated with an increased risk of mortality in children with juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2012, 64(Suppl 10):S127-S128.
14. Lorenzoni P.J., Scola R.H., Kay C.S., et al. Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases. Pediatr Neurol 2011, 45:17-22.
15. Gerami P., Walling H.W., Lewis J., et al. Asystematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007, 157:637-644.
16. Mukamel M., Brik R. Amyopathic dermatomyositis in children: a diagnostic and therapeutic dilemma. JClin Rheumatol 2001, 7:191-193.
17. Plamondon S., Dent P.B. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. JRheumatol 2000, 27:2031-2034.
18. Dimachkie M.M., Barohn R.J. Inclusion body myositis. Curr Neurol Neurosci Rep 2013, 13:321.
19. Limaye V., Luke C., Tucker G., et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013, 33:965-971.
20. Ibarra M., Chou P., Pachman L.M. Ovarian teratoma mimicking features of juvenile dermatomyositis in a child. Pediatrics 2011, 128:e1293-e1296.
21. Morris P., Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. JPediatr Hematol Oncol 2010, 32:189-191.
22. Auerbach A., Fanburg-Smith J.C., Wang G., et al. Focal myositis: a clinicopathologic study of 115 cases of an intramuscular mass-like reactive process. Am J Surg Pathol 2009, 33:1016-1024.
23. Smith A.G., Urbanits S., Blaivas M., et al. Clinical and pathologic features of focal myositis. Muscle Nerve 2000, 23:1569-1575.
24. Fraser C.L., Skalicky S.E., Gurbaxani A., et al. Ocular myositis. Curr Allergy Asthma Rep 2013, 13:315-321.
25. Costa R.M., Dumitrascu O.M., Gordon L.K. Orbital myositis: diagnosis and management. Curr Allergy Asthma Rep 2009, 9:316-323.
26. Wallace Z.S., Khosroshahi A., Jakobiec F.A., et al. IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvement. Surv Ophthalmol 2012, 57:26-33.
27. Kondolot M., Unal E., Poyrazoglu G., et al. Orbital myositis associated with focal active colitis in a teenage girl. Childs Nerv Syst 2012, 28:641-643.
28. Rouster-Stevens K.A., Pachman L.M. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. JRheumatol 2008, 35:927-929.
29. Israeli E., Agmon-Levin N., Blank M., et al. Macrophagic myofasciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol 2011, 41:163-168.
30. Gruis K.L., Teener J.W., Blaivas M. Pediatric macrophagic myofasciitis associated with motor delay. Clin Neuropathol 2006, 25:172-179.
31. Rivas E., Gomez-Arnaiz M., Ricoy J.R., et al. Macrophagic myofasciitis in childhood: a controversial entity. Pediatr Neurol 2005, 33:350-356.
32. Lach B., Cupler E.J. Macrophagic myofasciitis in children is a localized reaction to vaccination. JChild Neurol 2008, 23:614-619.
33. Pickering M.C., Walport M.J. Eosinophilic myopathic syndromes. Curr Opin Rheumatol 1998, 10:504-510.
34. Dourmishev L.A., Dourmishev A.L. Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations. Expert Opin Drug Saf 2008, 7:421-433.
35. Brown R.H., Amato A. Calpainopathy and eosinophilic myositis. Ann Neurol 2006, 59:875-877.
36. Baumeister S.K., Todorovic S., Milic-Rasic V., et al. Eosinophilic myositis as presenting symptom in gamma-sarcoglycanopathy. Neuromuscul Disord 2009, 19:167-171.
37. Hewer E., Goebel H.H. Myopathology of non-infectious inflammatory myopathies - the current status. Pathol Res Pract 2008, 204:609-623.
38. Le R.K., Streichenberger N., Vial C., et al. Granulomatous myositis: a clinical study of thirteen cases. Muscle Nerve 2007, 35:171-177.
39. Wong N.L., Di F. Pseudosarcomatous fasciitis and myositis: diagnosis by fine-needle aspiration cytology. Am J Clin Pathol 2009, 132:857-865.
40. Talbert R.J., Laor T., Yin H. Proliferative myositis: expanding the differential diagnosis of a soft tissue mass in infancy. Skeletal Radiol 2011, 40:1623-1627.
41. Stevens A.M., Sullivan K.M., Nelson J.L. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 2003, 42:34-39.
42. Pegoraro E., Mancias P., Swerdlow S.H., et al. Congenital muscular dystrophy withprimary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol 1996, 40:782-791.
43. Ravelli A., Trail L., Ferrari C., et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010, 62:63-72.
44. Stringer E., Singh-Grewal D., Feldman B.M. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008, 58:3585-3592.
45. Christen-Zaech S., Seshadri R., Sundberg J., et al. Persistent association of nail fold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008, 58:571-576.
46. Miles L., Bove K.E., Lovell D., et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007, 57:1183-1191.
47. Kim S., El-Hallak M., Dedeoglu F., et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009, 60:1825-1830.
48. Eidelman N., Boyde A., Bushby A.J., et al. Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Res Ther 2009, 11:R159.
49. Aikawa N.E., Jesus A.A., Liphaus B.L., et al. Organ-specific autoantibodies and autoimmune diseases in juvenile systemic lupus erythematosus and juvenile dermatomyositis patients. Clin Exp Rheumatol 2012, 30:126-131.
50. Mamyrova G., Katz J.D., Jones R.V., et al. Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy. Arthritis Care and Reseach 2013, in press.
51. Gerami P., Schope J.M., McDonald L., et al. Asystematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. JAm Acad Dermatol 2006, 54:597-613.
52. Abe Y., Koyasu Y., Watanabe S., et al. Juvenile amyopathic dermatomyositis complicated by progressive interstitial pneumonia. Pediatr Int 2010, 52:149-153.
53. Kalil R.K., Monteiro A., Lima M.I., et al. Macrophagic myofasciitis in childhood: the role of scanning electron microscopy/energy-dispersive spectroscopy for diagnosis. Ultrastruct Pathol 2007, 31:45-50.
54. Rider L.G., Shah M., Mamyrova G., et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 2013, 92(4):223-243.
55. Gunawardena H., Wedderburn L.R., North J., et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008, 47:324-328.
56. Trallero-Araguas E., Rodrigo-Pendas J.A., Selva-O'Callaghan A., et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012, 64:523-532.
57. Gunawardena H., Wedderburn L.R., Chinoy H., et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009, 60:1807-1814.
58. Espada G., Maldonado Cocco J.A., Fertig N., et al. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. JRheumatol 2009, 36:2547-2551.
59. Kobayashi I., Okura Y., Yamada M., et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. JPediatr 2011, 158:675-677.
60. Sakurai N., Nagai K., Tsutsumi H., et al. Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement. JRheumatol 2011, 38:963-964.
61. Koga T., Fujikawa K., Horai Y., et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012, 51:1278-1284.
62. Cao H., Pan M., Kang Y., et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012, 64:1602-1610.
63. Fujimoto M., Hamaguchi Y., Kaji K., et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012, 64:513-522.
64. Fujimoto M., Matsushita T., Hamaguchi Y., et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 2013, 72:151-153.
65. Tarricone E., Ghirardello A., Rampudda M., et al. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. JImmunol Methods 2012, 384:128-134.
66. Vancsa A., Gergely L., Ponyi A., et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010, 77:125-130.
67. Koenig M., Fritzler M.J., Targoff I.N., et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007, 9:R78.
68. Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012, 41:890-899.
69. Mahler M., Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437.
70. Marie I., Lahaxe L., Benveniste O., et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010, 162:337-344.
71. Rigolet A., Musset L., Dubourg O., et al. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore) 2012, 91:95-102.
72. Targoff I.N., Mamyrova G., Trieu E.P., et al. Anovel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689.
73. Ghirardello A., Rampudda M., Ekholm L., et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010, 49:2370-2374.
74. Rider L.G., Werth V.P., Huber A.M., et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011, 63(Suppl 11):S118-S157.
75. Rider L.G., Giannini E.H., Brunner H.I., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281-2290.
76. Ruperto N., Pistorio A., Ravelli A., et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010, 62:1533-1541.
77. Oddis C.V., Reed A.M., Aggarwal R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013, 65:314-324.
78. Ruperto N., Pistorio A., Oliveira S., et al. Arandomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate. Arthritis Rheum 2012, 64(Suppl 10):S1042-S1043.
79. Huber A.M., Giannini E.H., Bowyer S.L., et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 2010, 62:219-225.
80. Huber A.M., Robinson A.B., Reed A.M., et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 2012, 64:546-553.
81. Seshadri R., Feldman B.M., Ilowite N., et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008, 59:989-995.
82. Rouster-Stevens K.A., Gursahaney A., Ngai K.L., et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008, 59:222-226.
83. Ramanan A.V., Campbell-Webster N., Ota S., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005, 52:3570-3578.
84. Lam C.G., Manlhiot C., Pullenayegum E.M., et al. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 2011, 70:2089-2094.
85. Dagher R., Desjonqueres M., Duquesne A., et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2012, 32:711-716.
86. Wilkes M.R., Sereika S.M., Fertig N., et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005, 52:2439-2446.
87. Hassan J., van der Net J.J., van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008, 27:1469-1471.
88. Riley P., Maillard S.M., Wedderburn L.R., et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004, 43:491-496.
89. Moraitis E., Arnold K., Pilkington C. Effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis - a national cohort study UK and Ireland [abstract]. Arthritis Rheum 2012, 64(Suppl 10):S130-S131.
90. Aggarwal R., Oddis C.V., Bandos A., et al. Effect of B cell depletion therapy with rituximab on myositis associated autoantibody levels in idiopathic inflammatory myopathy. Arthritis Rheum 2012, 64(Suppl 10):S325.
91. Rios F.R., Callejas Rubio J.L., Sanchez C.D., et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009, 27:1009-1016.
92. Cooper M.A., Willingham D.L., Brown D.E., et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007, 56:3107-3111.
93. Chung L., Genovese M.C., Fiorentino D.F. Apilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767.
94. Riley P., McCann L.J., Maillard S.M., et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008, 47:877-880.
95. Boulter E.L., Beard L., Ryder C., et al. Juvenile Dermatomyositis Research Group. Effectiveness of anti-tumor necrosis factor- agents in the treatment of refractory juvenile dermatomyositis. Arthritis Rheum 2011, 63(Suppl 10):S795.
96. Aggarwal R., Oddis C.V. Therapeutic advances in myositis. Curr Opin Rheumatol 2012, 24:635-641.
97. Nagaraju K., Lundberg I.E. Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin North Am 2011, 37:159-171. v.
98. Rider L.G., Lachenbruch P.A., Monroe J.B., et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009, 60:3425-3435.
99. Robinson A.B., Reed A.M. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011, 7:664-675.
100. Stringer E., Bohnsack J., Bowyer S.L., et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. JRheumatol 2010, 37:1953-1961.
101. Hasija R., Pistorio A., Ravelli A., et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011, 63:3142-3152.
102. Dalakas M.C., Illa I., Dambrosia J.M., et al. Acontrolled trial of high-does intravenous immune globulin infusions as treatment for dermatomyositis. NEngl J Med 1993, 329:1993-2000.
103. Manlhiot C., Tyrrell P.N., Liang L., et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics 2008, 121:e626-e630.
104. Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther 2012, 6:133-139.
105. Chiu Y.E., Co D.O. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol 2011, 28:357-367.
106. de Visser M. The efficacy of rituximab in refractory myositis: the jury is still out. Arthritis Rheum 2013, 65:303-306.
107. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012, 64:3043-3051.
108. Mamyrova G., O'Hanlon T.P., Sillers L., et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008, 58:3941-3950.
109. Coyle K., Pokrovnichka A., French K., et al. Arandomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Rheum 2008, 58(Suppl 9):S923-S924.
110. Hengstman G.J., van den Hoogen F.H., Barrera P., et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003, 50:10-15.
111. Hengstman G.J., De Bleecker J.L., Feist E., et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59:159-163.
112. Dastmalchi M., Grundtman C., Alexanderson H., et al. Ahigh incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008, 67:1670-1677.
113. Miller M.L., Smith R.L., Abbott K.A., et al. Use of etanercept in chronic juvenile dermatomyositis (JDM). Arthritis Rheum 2002, 46(Suppl 9):S306.
114. Muscle Study Group Arandomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011, 70:427-436.
115. Klein R., Rosenbach M., Kim E.J., et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010, 146:780-784.
116. Zong M., Dorph C., Dastmalchi M., et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 2013, [Epub ahead of print].
117. Higgs B.W., Zhu W., Morehouse C., et al. Aphase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2013, [Epub ahead of print].
118. Arabshahi B., Silverman R.A., Jones O.Y., et al. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. JPediatr 2012, 160:520-522.
119. Narazaki M., Hagihara K., Shima Y., et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011, 50:1344-1346.
120. Reiff A., Shaham B., Weinberg K.I., et al. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis. JClin Immunol 2011, 31:615-622.
121. Dalakas M.C., Rakocevic G., Schmidt J., et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009, 132:1536-1544.
122. Wu F.Q., Luan Z., Lai J.M., et al. Treatment of refractory rheumatism among preschool children with autologous peripheral blood hematopoietic stem cell transplantation. Zhonghua Er Ke Za Zhi 2007, 45:809-813.
123. Holzer U., van Royen-Kerkhof A., van der Torre P., et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010, 39:88-92.
124. Shah M., Targoff I.N., Rice M.M., et al. Childhood Myositis Heterogeneity Collaborative Study Group. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 2013, 65(7):1934-1941.
125. Widel M. Bystander effect induced by UV radiation; why should we be interested?. Postepy Hig Med Dosw (Online) 2012, 66:828-837.
126. Kripke M.L. Reflections on the field of photoimmunology. JInvest Dermatol 2013, 133:27-30.
127. Walling H.W., Gerami P., Sontheimer R.D. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management. Paediatr Drugs 2010, 12:23-34.
128. Sambandan D.R., Ratner D. Sunscreens: an overview and update. JAm Acad Dermatol 2011, 64:748-758.
129. Wang S.Q., Balagula Y., Osterwalder U. Photoprotection: a review of the current and future technologies. Dermatol Ther 2010, 23:31-47.
130. Shrestha S., Wershil B., Sarwark J.F., et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 2010, 62:2813-2822.
131. Olsen N.J., Schleich M.A., Karp D.R. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum 2013, pii:S0049-0172(13)00006-1. [Epub ahead of print]. 10.1016/j.semarthrit.2013.01.001.
132. Matsuda H., Goto M., Fujiwara S. Successful treatment of intractable ulceration associated with dermatomyositis by debridement and the skin implantation of an artificial dermis sheet. JDermatol 2011, 38:1027-1030.
133. Chander S., Gordon P. Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol 2012, 24:158-164.
134. Gutierrez A., Wetter D.A. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther 2012, 25:195-206.
135. Mathiesen P.R., Orngreen M.C., Vissing J., et al. Aerobic fitness after JDM-a long-term follow-up study. Rheumatology (Oxford) 2013, 52:287-295.
136. Maillard S.M., Jones R., Owens C.M., et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 2005, 53:558-564.
137. Alexanderson H., Lundberg I.E. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012, 24:201-207.
138. Omori C.H., Silva C.A., Sallum A.M., et al. Exercise training in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2012, 64:1186-1194.